ReviewMolecular cancer2004
Molecular regulation of pancreatic stellate cell function.
Review in Molecular cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 148 citations in OpenAlex.
- Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer.BMC cancer · 2011Trial
- Nanotherapy for Pancreatitis: From Single-Cell Targeting Toward Multicellular-Coordinated Regulation.International journal of nanomedicine · 2026Review
- Deciphering cellular plasticity in pancreatic cancer for effective treatments.Cancer metastasis reviews · 2024Review
- Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.Clinical and experimental medicine · 2023Review
- Yttrium Oxide Nanoparticles Attenuate L-Arginine Induced Chronic Pancreatitis.Biological trace element research · 2023Article
- Deletion of the mRNA stability factorNAR cancer · 2023Article
- Sterile Pancreas Inflammation during Preservation and after Transplantation.International journal of molecular sciences · 2023Review
- Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer.Frontiers in oncology · 2023Review
- Review
- Regulation of Mesothelial Cell Fate during Development and Human Diseases.International journal of molecular sciences · 2022Review
- Pancreatic Stellate Cells Prolong Ex Vivo Islet Viability and Function and Improve Engraftment.Stem cells translational medicine · 2022Article
- Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment.Frontiers in immunology · 2022Review
- Immune cells regulate matrix metalloproteinases to reshape the tumor microenvironment to affect the invasion, migration, and metastasis of pancreatic cancer.American journal of translational research · 2022Article
- Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer.Cancers · 2021Article
- TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Inhibitory Smads suppress pancreatic stellate cell activation through negative feedback in chronic pancreatitis.Annals of translational medicine · 2021Article
- The effects of nuclear factor-kappa B in pancreatic stellate cells on inflammation and fibrosis of chronic pancreatitis.Journal of cellular and molecular medicine · 2021Article
- Distinct Murine Pancreatic Transcriptomic Signatures during Chronic Pancreatitis Recovery.Mediators of inflammation · 2021Article
- Molecular Mechanism of Pancreatic Stellate Cells Activation in Chronic Pancreatitis and Pancreatic Cancer.Journal of Cancer · 2020Review
- Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy.Cell biology and toxicology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until now, no specific therapies are available to inhibit pancreatic fibrosis, a constant pathological feature of chronic pancreatitis and pancreatic cancer. One major reason is the incomplete knowledge of the molecular principles underlying fibrogenesis in the pancreas. In the past few years, evidence has been accumulated that activated pancreatic stellate cells (PSCs) are the predominant source of extracellular matrix (ECM) proteins in the diseased organ. PSCs are vitamin A-storing, fibroblast-like cells with close morphological and biochemical similarities to hepatic stellate cells (also known as Ito-cells). In response to profibrogenic mediators such as various cytokines, PSCs undergo an activation process that involves proliferation, exhibition of a myofibroblastic phenotype and enhanced production of ECM proteins. The intracellular mediators of activation signals, and their antagonists, are only partially known so far. Recent data suggest an important role of enzymes of the mitogen-activated protein kinase family in PSC activation. On the other hand, ligands of the nuclear receptor PPARgamma (peroxisome proliferator-activated receptor gamma) stimulate maintenance of a quiescent PSC phenotype. In the future, targeting regulators of the PSC activation process might become a promising approach for the treatment of pancreatic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.